Dr. Kenneth Kohn serves as Chairman of the Board of Directors at ARMR Sciences Inc., where he provides strategic oversight on intellectual property strategy, corporate governance, and long-term value protection. He brings more than 30 years of experience in intellectual property law, portfolio development, and complex litigation within the health sciences and biotechnology sectors.

Dr. Kohn is currently Principal Executive at Kohn & Associates, where he advises biotechnology companies, research institutions, and pharmaceutical organizations on patent protection, enforcement, and strategic IP positioning. Throughout his career, he has played a central role in high-profile matters across emerging scientific domains, including intellectual property coverage in the CRISPR gene-editing space, early breast cancer gene and intron research for Francis Collins, dendritic chemistry portfolios for NIH-supported research led by Dr. George Newkome, blood chemistry analysis technologies for Difco Sciences (now part of Becton Dickinson), and intellectual property strategy supporting Pfizer during the launch of Lyrica.

In addition to his legal and advisory work, Dr. Kohn has published scientific research on porphyrin and prostaglandin chemistry in leading journals and has presented at numerous conferences addressing prominent intellectual property challenges in the life sciences sector.

He is an active member or affiliate of several professional organizations, including the American Bar Association, the Association of University Technology Managers (AUTM), the Economic Club of Detroit, the Michigan Biosciences Industry Association, the Michigan Patent Law Association, and the State Bar of Michigan.

Dr. Kohn earned his Juris Doctor (JD) from Wayne State University Law School. He also holds a Doctor of Philosophy (PhD) in Pharmacology, with a minor in Immunology, from Wayne State University School of Medicine.